The β-carboline Harmine improves the therapeutic benefit of anti-PD1 in melanoma by increasing the MHC-I-dependent antigen presentation

The β-carboline Harmine improves the therapeutic benefit of anti-PD1 in melanoma by increasing the MHC-I-dependent antigen presentation

Harmine is a dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor that displays a number of biological and pharmacological properties. Also referred to as ACB1801 molecule, we have previously reported that harmine increases the presentation of major histocompatibility complex (MHC)-I-dep...

Full description

Bibliographic Details
Main Authors: Muhammad Zaeem Noman, Irene Adelaide Bocci, Manale Karam, Kris Van Moer, Manon Bosseler, Akinchan Kumar, Guy Berchem, Christian Auclair, Bassam Janji
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Immunology
Subjects:
MHC-I antigen presentation
harmine
DYRK1A
anti-PD1 Immunotherapy
T lymphocyte and NK cells infiltration
melanoma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.980704/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.980704/full

Similar Items